Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

From UNC Student Reporter to Olympics Writer
An interview with a UNC student-reporter must have felt like looking in a mirror. Sean Cavanaugh ’17, a reporter for the Olympic Broadcasting Services (OBS)...
Tue Mar 24, 2026

AI research at Carolina
From computer science to journalism, health sciences to social work, researchers are applying AI to the world’s problems. Carolina already boasts a deep knowledge of...
Sun Mar 22, 2026

From an indigo hue to Carolina Blue: the history behind UNC's school colors
Many students, fans and alums have proudly proclaimed that UNC is home to "the better blue." Carolina Blue became a widely used noun in the...
Sat Mar 21, 2026

Entrepreneur, UNC alum gives back, a bagel at a time
Alex Brandwein left UNC Kenan-Flagler Business School in May 2020 with two big accomplishments: an MBA and a lease for a bagel shop a few...
Tue Mar 17, 2026